丁型肝炎的经济与医疗负担:美国商业保险成人研究
基于2011-2014年Truven Health MarketScan商业理赔数据库的病例对照研究,将2,727例HDV病例按社会人口学特征和合并症1:1匹配慢性HBV对照。HDV组物质滥用、性传播疾病、失代偿性肝硬化、肝硬化和丙型肝炎患病率显著更高。首次HDV诊断与总索赔数(25.61 vs 28.99)和年度总医疗费用($19,476 vs $23,605)显著增加相关。病例对照分析显示HDV较单纯HBV总索赔数(28.99 vs 25.19)和医疗费用($23,605 vs $18,228)更高。
要点
- HDV患者较单纯HBV患者年度总索赔数和医疗费用显著更高
- HDV组肝硬化、失代偿性肝硬化和丙型肝炎患病率显著高于HBV组
- HDV诊断与医疗使用和费用负担增加相关,需加强筛查和治疗
核心结论
- HDV与较单纯HBV更高的医疗使用和费用负担相关,强调改进筛查和治疗的必要性。
研究设计与样本
- 病例对照研究,使用2011-2014年Truven Health MarketScan商业理赔数据库,2,727例HDV病例按社会人口学特征和合并症1:1倾向评分匹配慢性HBV对照。
主要发现
- HDV组物质滥用、性传播疾病、失代偿性肝硬化、肝硬化和丙型肝炎患病率显著高于慢性HBV患者。
- 首次HDV诊断与总索赔数(25.61 vs 28.99;P < 0.0001)和年度总医疗费用($19,476 vs $23,605;P < 0.0001)较HDV前基线显著增加相关。
- 病例对照分析显示HDV较单纯HBV总索赔数(28.99 vs 25.19;P < 0.0001)和医疗费用($23,605 vs $18,228;P < 0.0001)更高。
- HDV病例较HBV对照年度总索赔数的调整发病率比为1.16(95%CI:1.10,1.22),年度总医疗费用的调整发病率比为1.32(95%CI:1.17,1.48)。
临床怎么用
- 对HBV患者应加强HDV筛查,以识别高负担人群并优化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The paucity of data regarding the extent of hepatitis delta virus (HDV) associated health care burden in the United States is an important obstacle to assessing the cost-effectiveness of potential intervention strategies. In this study, we characterized the health care use and cost burdens of HDV in the United States using real-world claims data. APPROACH AND RESULTS: We conducted a case-control study using the Truven Health MarketScan Commercial Claims databases from 2011-2014. A total of 2,727 HDV cases were matched 1:1 by sociodemographic characteristics and comorbidities to chronic hepatitis B virus (HBV) controls using propensity scores. The HDV group had significantly higher prevalence of substance abuse, sexually transmitted diseases, decompensated cirrhosis, cirrhosis, and hepatitis C virus compared to patients with chronic HBV. First HDV diagnosis was associated with significant increases in the total number of health care claims (25.61 vs. 28.99; P < 0.0001) and total annual health care costs ($19,476 vs. $23,605; P < 0.0001) compared with pre-HDV baseline. The case-control analysis similarly indicated higher total claims (28.99 vs. 25.19; P < 0.0001) and health care costs ($23,605 vs. $18,228; P < 0.0001) in HDV compared with HBV alone. Compared with HBV controls, HDV cases had an adjusted incident rate ratio of 1.16 (95% confidence interval: 1.10, 1.22) times the total number of annual claims and an adjusted incident rate ratio 1.32 (95% confidence interval 1.17, 1.48) times the total annual health care cost. CONCLUSIONS: HDV is associated with higher health care use and cost burden than HBV alone, underscoring the need for improved screening and treatment.
引用
- Elsaid MI, Li Y, John T, et al. Economic and Health Care Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States. Hepatology. 2020. PMID: 31804707. doi:10.1002/hep.31055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。